TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01254630

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V212
Description: V212 viral antigen for HZ, 0.5 mL subcutaneous (SC) injection per dose, in a four dose regimen, approximately 30 days apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart.
Study: NCT03715101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Open-label, one-sequence, multiple administration
Study: NCT01909453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818- Orally 100 mg and 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162- Orally 15 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Description: MEK162- Orally 15 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vemurafenib
Description: Tablets in bottles or blisters 240 mg
Study: NCT04228965

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Counseling
Description: Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Psychosocial counseling will be administered by trained research staff leading up to the target quit date and throughout the study. Counseling will include motivational enhancement for medication adherence and tobacco cessation. The content of counseling will be skills-based and will focus on enlisting social support, recognizing smoking triggers, managing craving/withdrawal/stress, etc.
Study: NCT00424450

Intervention type: PROCEDURE
Intervention: lower limb artery bypass surgery
Description: bypass of severe atherosclerotic vascular lesion

Intervention type: PROCEDURE
Intervention: percutaneous angioplasty (PTA)
Description: PTA of severe atherosclerotic lesion
Study: NCT04150055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Coach
Description: Mindfulness Coach is an mHealth delivered mindfulness therapy.
Study: NCT04040946

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MIBI scintigraphy
Description: Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MIBI scintigraphy
Description: Performing a MIBI scintigraphy, then, in the case of negativity, a single F18-choline PET

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F18-choline PET
Description: Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: F18-choline PET
Description: Realization of a F18-choline PET, then, in case of negativity, a MIBI scintigraphy
Study: NCT01689636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc 99m EC20
Study: NCT00912860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: serum free Avonex given IM once a week
Study: NCT02398656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiplatelet treatment
Description: Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
Study: NCT01020383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALX-0081
Description: 4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ReoPro®
Description: 0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
Study: NCT04232774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Neurotronic arterial ablation catheter
Description: a sterile, single use catheter (device) for delivering chemical agent to achieve perivascular denervation.
Study: NCT00589212

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GliaSite Radiation Therapy System
Description: GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
Study: NCT00618280

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nicotine nasal spray
Description: 0,5 mg nicotine nasal spray or placebo (pepperspray)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine nasal spray
Description: 0,5 mg nicotine nasal spray or placebo (pepperspray)
Study: NCT03299491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MWA intervention
Description: The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IEC intervention
Description: Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IEC intervention
Description: Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.~Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.~Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences.
Study: NCT03631563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressive Agent
Description: ATG-Fresenius versus ATG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunosuppressive Agent
Description: ATG-Fresenius versus ATG
Study: NCT02141347

Intervention type: DRUG
Group type: OTHER
Intervention: Tremelimumab
Description: Tremelimumab administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Tremelimumab
Description: Tremelimumab administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: Tremelimumab
Description: Tremelimumab administered intravenously

Intervention type: DRUG
Group type: OTHER
Intervention: MEDI4736
Description: MEDI4736 administered intravenously.
Study: NCT00697892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir
Description: Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efavirenz
Description: One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
Study: NCT01440244

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cervical mediastinoscopy
Description: minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
Study: NCT01306669

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent influenza vaccine
Description: single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
Study: NCT03588975

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MACI
Description: autologous cultured chondrocytes on porcine collagen membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microfracture
Description: Arthroscopic microfracture treatment
Study: NCT00603447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
Study: NCT03293264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training group
Description: Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .~Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome.
Study: NCT04164628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Description: Quality of life will be assessed with Nottingham Health Profile
Study: NCT04162366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan 25 mg
Description: Tablet, oral use once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet, oral use once daily
Study: NCT04106830

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).

Intervention type: DRUG
Intervention: Intravenous steroid
Description: This study does not limit treatment methods.patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. The HD-S treatment course referred to intravenous administration of 1 g of glucocorticoid daily for 3 consecutive days and continuous dose 240 mg reduction for 60mg oral administration. Immunomodulatory therapies are necessary for the remission stage. The treatment methods include: Azathioprine (start at 50 mg per day, add 50 mg per week to 2 mg/kg.d); Mycophenolate Mofetil (The initial dose was 0.25g bid, add 0.5g per week to 0.75g bid); and Rituximab (500 mg on the 1st day, the 15th day, then 500mg per half year).
Study: NCT03566108

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA
Description: Vestibular incision supraperiosteal tunnel access (VISTA) incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: STA
Description: Sulcular tunnel access incision will be performed on all individuals in this arm of the study to facilitate coronal advancement of the gingival flap and placement of acellular dermal matrix
Study: NCT03529331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate Immediate Release
Description: 15 mg Morphine Sulfate Immediate Release (MSIR) tablet 4 times a day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone/Acetaminophen
Description: 5 mg of Oxycodone/Acetaminophen (Percocet) tablet 4 times a day for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen
Description: 5 mg of Hydrocodone/Acetaminophen (Vicodin) tablet 4 times a day for 5 days
Study: NCT04275934

Intervention type: BEHAVIORAL
Intervention: Health Management; Blood Pressure
Description: Pharmacists will work with the patient/study subject, referred to as the participant hereafter, and the participant's other health care providers to manage their blood pressure, making recommendations for medication and lifestyle adjustments as needed.
Study: NCT02318537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Solution
Description: An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Solution
Description: A matching oral solution containing no cannabidiol.
Study: NCT01847742

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing Therapy
Study: NCT04306029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postpartum Family Planning Package
Description: Postpartum Family Planning Package, which consists of provider education on contraceptive delivery in the immediate postpartum period and promotion of the WHO MEC/PFP Compendium mobile application.
Study: NCT04108234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR071603
Description: HR071603 monotherapy ,nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo,nasal spray
Study: NCT00316992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon and Placebo
Description: Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
Study: NCT02592525

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-SDM training for health professionals
Description: Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-SDM training for health professionals
Description: Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-SDM training for health professionals
Description: Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IP-SDM training for health professionals
Description: Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
Study: NCT01363648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: choline alfoscerate
Description: Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for choline alphoscerate)
Description: Pill manufactured to mimic choline alfoscerate 400mg tablet
Study: NCT02827227

Intervention type: BIOLOGICAL
Intervention: lymphocytes immunophenotyping
Description: The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.~HIV patients with a known history of PHI and a minimum of 2 years of effective cART (\< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).~Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.~Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded.
Study: NCT02245984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: paper based nursing process
Description: for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic nursing process
Description: for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
Study: NCT03216187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 150 mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: capsules identical to pregabalin but without active drug
Study: NCT02235805

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
Study: NCT03565601

Intervention type: OTHER
Intervention: Follow-up
Description: Clinical data, radiological data and laboratory tests follow-up
Study: NCT04162366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet, oral use once daily
Study: NCT01178515

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Modification of the content of fat in milk
Description: Comparison of three levels of fat content in cow´s milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of the content of cows milk
Description: Comparison of three levels of fat content in cows' milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modification of the fat content of cows´ milk
Description: Comparison of three levels of fat content in cow´milk